Michael Ulz
Stock Analyst at Morgan Stanley
(0.39)
# 1696
Out of 5,293 analysts
160
Total ratings
37.93%
Success rate
5.25%
Average return
Main Sectors:
Top Industries:
Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
KYTX Kyverna Therapeutics | Maintains: Overweight | 40 20 | 1.98 | 910.1% | 2 | Apr 1, 2025 | |
CABA Cabaletta Bio | Maintains: Overweight | 30 22 | 1.16 | 1796.55% | 6 | Apr 1, 2025 | |
AARD Aardvark Therapeutics | Initiates Coverage On: Overweight | 29 | 8.25 | 251.52% | 1 | Mar 10, 2025 | |
YMAB Y-mAbs Therapeutics | Maintains: Underweight | 11 7 | 4.5 | 55.56% | 7 | Mar 5, 2025 | |
SLN Silence Therapeutics | Maintains: Overweight | 49 45 | 2.42 | 1759.5% | 11 | Mar 5, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 75 54 | 3.55 | 1421.13% | 5 | Mar 3, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 24 20 | 3.25 | 515.38% | 4 | Feb 28, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 275 284 | 255.81 | 11.02% | 9 | Feb 14, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 20 5 | 3.37 | 48.37% | 5 | Feb 12, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 18 10 | 1.11 | 800.9% | 2 | Feb 3, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 46 96 | 38.63 | 148.51% | 4 | Jan 28, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 105 105 | 23.89 | 339.51% | 2 | Sep 12, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 48 52 | 9.22 | 463.99% | 2 | Aug 14, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 110 115 | 86 | 33.72% | 9 | Jul 12, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 53 57 | 44.04 | 29.43% | 3 | Jun 18, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 36 27 | 12.21 | 121.13% | 4 | May 13, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 47 65 | n/a | n/a | 4 | Apr 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 3 7 | 0.78 | 797.44% | 8 | Feb 27, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 23 12 | n/a | n/a | 4 | Jan 5, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 45 48 | 27.25 | 76.15% | 4 | Nov 3, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 15 27 | 5.54 | 387.36% | 2 | Aug 16, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 42 37 | n/a | n/a | 9 | Aug 9, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 35 40 | n/a | n/a | 4 | May 1, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 30 20 | 3.2 | 525% | 3 | Mar 24, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 45 | 5.81 | 674.53% | 1 | Feb 1, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 20 10 | 0.68 | 1370.59% | 3 | Jan 27, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 6 8 | 0.22 | 3536.36% | 5 | Jan 27, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 3 | 1.26 | 138.1% | 1 | Jan 27, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Equal-Weight | 18 30 | 6.18 | 385.44% | 1 | Jan 27, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 135 90 | n/a | n/a | 3 | Aug 4, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 15 7 | n/a | n/a | 3 | May 11, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 25 30 | 1.15 | 2508.7% | 3 | Mar 30, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | n/a | n/a | n/a | 1 | Feb 1, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 84 36 | n/a | n/a | 2 | Jan 5, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 45 | 5.63 | 699.29% | 1 | Oct 8, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 500 | n/a | n/a | 1 | Sep 23, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 12 20 | 0.33 | 5960.61% | 2 | May 28, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 30 | n/a | n/a | 1 | Apr 16, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 3 1 | n/a | n/a | 4 | Mar 29, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 7 4 | n/a | n/a | 3 | Oct 22, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 17 0 | n/a | n/a | 2 | Sep 21, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 680 544 | n/a | n/a | 2 | Jun 13, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 85 80 | 33.84 | 136.41% | 2 | Nov 3, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 12 15 | 7.95 | 88.68% | 3 | Jul 12, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 127 182 | n/a | n/a | 2 | Feb 27, 2017 |